Key result
TACE plus iodine-125 seeds achieves complete response and 6-year recurrence-free survival in one osteosarcoma patient.
Why the study?
Surgery and systemic chemotherapy for osteosarcoma carry significant trauma and toxicity that some patients decline, highlighting the need for alternative local treatment options.
Does TACE combined with iodine-125 seed implantation improve outcomes in a patient with osteosarcoma who declines surgery?
Case Report (n=1)
No
Does TACE combined with iodine-125 seed implantation improve outcomes in a patient with osteosarcoma who declines surgery?
TACE combined with iodine-125 seed implantation may offer an effective, low-toxicity alternative for local tumor control in osteosarcoma patients who decline surgery.
Non-surgical local therapy yielded 6-year remission in one surgery-refusing case; leaves open its broader role in osteosarcoma.
Osteosarcoma is a highly malignant bone tumor that predominantly affects adolescents. Its aggressive nature, complex treatment options and poor prognosis render it a notable concern in oncology. With advancements in therapy for osteosarcoma, neoadjuvant chemotherapy in conjunction with limb-salvage surgery has emerged as the preferred surgical strategy. However, the physical and emotional trauma associated with surgery, along with the adverse side effects of chemotherapy, can be unacceptable to some patients. In recent years, alternative local treatment modalities such as transarterial chemoembolization (TACE) and iodine-125 seed implantation have garnered considerable attention. These techniques show potential in enhancing local tumor control while minimizing systemic toxicity. TACE involves obstructing the blood supply to the tumor while administering localized chemotherapy, resulting in tumor ischemia and necrosis, which is particularly effective for hypervascular tumors. Meanwhile, iodine-125 seeds act as low-energy radiation sources that can effectively target tumor cells while sparing the surrounding healthy tissue. The present study describes a case of osteosarcoma treated with a combination of TACE and iodine-125 seed implantation. The patient, diagnosed with osteosarcoma of the left knee joint, declined surgical intervention. Consequently, a treatment plan involving TACE paired with iodine-125 seed implantation was established. Post-treatment follow-up demonstrated marked pain relief, improved limb function and a notable reduction in tumor volume with decreased bone destruction visible on imaging. Over a follow-up period of 6 years, there were no signs of disease recurrence or distant metastasis, and no notable chemotherapy-related side effects were reported. The quality of life of the patient was markedly improved. The current case illustrates the antitumor efficacy and reduced toxicity of combining TACE with iodine-125 seed implantation in the management of osteosarcoma.
No takes yet. Share an insight, caveat, or question.
Ran et al. (2025) conducted a case report in Stage IIB osteosarcoma (n=1). Transarterial chemoembolization (TACE) combined with iodine-125 seed implantation was evaluated on Clinical and radiological response. TACE combined with iodine-125 seed implantation achieved a complete pathological response, pain relief, and no recurrence over 6 years in a patient with stage IIB osteosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: